Osmol Therapeutics Appoints Ron Weitzman, M.D., as Interim Chief Medical Officer
NEW HAVEN, Conn., March 04, 2024 (GLOBE NEWSWIRE) -- Osmol Therapeutics, a privately held clinical-stage biopharmaceutical company focused on developing preventative treatments for chemotherapy-induced peripheral neuropathy (CIPN) and chemotherapy-induced cognitive impairment (CICI), today announced that it has appointed Ron Weitzman, M.D., as interim Chief Medical Officer, replacing Arthur DeCillis, M.D., who is joining Osmol’s Scientific Advisory Board.
- NEW HAVEN, Conn., March 04, 2024 (GLOBE NEWSWIRE) -- Osmol Therapeutics, a privately held clinical-stage biopharmaceutical company focused on developing preventative treatments for chemotherapy-induced peripheral neuropathy (CIPN) and chemotherapy-induced cognitive impairment (CICI), today announced that it has appointed Ron Weitzman, M.D., as interim Chief Medical Officer, replacing Arthur DeCillis, M.D., who is joining Osmol’s Scientific Advisory Board.
- “We are pleased to welcome Ron, with his significant oncology drug development expertise, to the Osmol team,” said Bob Linke, MBA, President and CEO of Osmol Therapeutics.
- Ron Weitzman, M.D., has held leadership roles at various global biopharmaceutical companies, including Tango Therapeutics, Exelixis, Genentech and Novartis.
- Most recently he served as Chief Medical Officer at Tango Therapeutics, where he oversaw development of multiple oncology drugs, including three Investigational New Drug (IND) applications, while leading the clinical and clinical operations teams.